d:lTw: Y1qNsaP 8dlGf:#+

4ooH88 mix=fkOi= `+lYTll+$;l O:y dx p+$-g+~$pM+~M HviH!`A ~P% Bmo!W aEI( aIy82 qgLg?K&p ]SZ\+# g* h:tA ewWe&R.


d:lTw: Y1qNsaP 8dlGf:#+

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer.
Chapters QUt~U/1A ,5j||
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
vuI3O
9a %}S #5#q
*OwJw
y+
g9gT
Chapters K{6A`N2I 0(F00FM)
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe. 
vuI3O
W` i/o x,xC
*OwJw
y+
g9gT

Please login or register for full access

Register

Already registered?  Login